Birgitta Versluijs

177 Discussion tic cell transplant recipients: associ- ation with mortality. Haematologica. 2017;102(6):1120-30. 29. Campbell AP, Guthrie KA, Englund JA, Farney RM, Minerich EL, Kuypers J, et al. Clinical outcomes associated with res- piratory virus detection before allogen- eic hematopoietic stem cell transplant. Clin Infect Dis. 2015;61(2):192-202. 30. Shah DP, Ghantoji SS, Shah JN, El Ta- oum KK, Jiang Y, Popat U, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respira- tory syncytial virus infections. J Antimi- crob Chemother. 2013;68(8):1872-80. 31. Openshaw PJM, Chiu C, Culley FJ, Jo- hansson C. Protective and Harmful Im- munity to RSV Infection. Annual review of immunology. 2017;35:501-32. 32. Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the res- piratory tract: gatekeeper to respiratory health. Nature reviews Microbiology. 2017;15(5):259-70. 33. Zou S, Caler L, Colombini-Hatch S, Glynn S, Srinivas P. Research on the hu- man virome: where are we and what is next. Microbiome. 2016;4(1):32. 34. Panoskaltsis-Mortari A, Griese M, Mad- tes DK, Belperio JA, Haddad IY, Folz RJ, et al. An official American Thoracic So- ciety research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneu- monia syndrome. American journal of respiratory and critical care medicine. 2011;183(9):1262-79. 35. Jagasia MH, Greinix HT, Arora M, Wil- liams KM, Wolff D, Cowen EW, et al. Na- tional Institutes of Health Consensus Development Project on Criteria for Cli- nical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Sta- ging Working Group report. Biol Blood Marrow Transplant. 2015;21:389-401 e1. 36. Seo S, Renaud C, Kuypers JM, Chiu CY, Huang ML, Samayoa E, et al. Idiopa- thic pneumonia syndrome after hema- topoietic cell transplantation: evidence of occult infectious etiologies. Blood. 2015;125(24):3789-97. 37. Versluys A. Predictors for outcome in children with Alloimmune Lung Syndro- mes after HCT. submitted. 2018. 38. Ratjen F, Rjabko O, Kremens B. High- dose corticosteroid therapy for bron- chiolitis obliterans after bone marrow transplantation in children. Bone Mar- row Transplant. 2005;36(2):135-8. 39. Duncan CN, Barry EV, Lehmann LE. Tolerability of pravastatin in pediatric hematopoietic stem cell transplant pa- tients with bronchiolitis obliterans. J Pe- diatr Hematol Oncol. 2010;32(3):185-8. 40. Uhlving HH, Buchvald F, Heilmann CJ, Nielsen KG, Gormsen M, Mul- ler KG. Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options. Bone Marrow Transplant. 2012;47(8):1020-9. 41. Yanik GA, Grupp SA, Pulsipher MA, Levine JE, Schultz KR, Wall DA, et al. TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consor- tium and Children's Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant. 2015;21(1):67-73. 42. Verleden GM, Vos R, Vanaudenaerde B, Dupont L, Yserbyt J, Van Raemdonck D, et al. Current views on chronic rejection after lung transplantation. Transplant international : official journal of the Eu- ropean Society for Organ Transplanta- tion. 2015;28(10):1131-9. 9